**Name of Journal:** *World Journal of Methodology*

**Manuscript NO:** 76205

**Manuscript Type:** MINIREVIEWS

**Reinfection, recontamination and revaccination for SARS-CoV-2**

Kullmann T *et al*. SARS-CoV-2 reinfection

Tamás Kullmann, András Drozgyik

**Tamás Kullmann,** Department of Medical Emergencies, Petz Aladár Hospital, Győr 9024, Hungary

**András Drozgyik,** Department of Surgery, Petz Aladár Hospital, Győr 9024, Hungary

**Author contributions:** Kullmann T and Drozgyik A contributed equally to this minireview.

**Corresponding author: Tamás Kullmann, PhD, Consultant Physician-Scientist,** Department of Medical Emergencies, Petz Aladár Hospital, Vasvári Pál u. 2-4, Győr 9024, Hungary. kullmanndoki@gmail.com

**Received:** March 7, 2022

**Revised:** April 22, 2022

**Accepted:** July 11, 2022

**Published online:**

**Abstract**

The reports on coronavirus disease 2019 (COVID-19) describe the pandemic in waves. Similar to the ocean’s waves, the frequency and amplitude of the number of new cases and the number of deaths were globally quite regular; nevertheless, they showed important regional irregularities and the direction of spread has been generally rather unpredictable for COVID-19. One of the major reasons for the repeated outbreaks is the mutating capacity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that allows the virus to infect persons who have natural immunity or have been vaccinated. Vaccination began in vast campaigns from the second year of the pandemic that was supposed to decrease the magnitude of the waves. Although it reduced the complications, the expected attenuation of the disease expansion has not yet been met. This paper provides a short overview of the most recent data on the rate of reinfection in vaccinated and non-vaccinated individuals. It points out that testing positive for a second time for SARS-CoV-2 does not necessarily mean a reinfection; it can also be interpreted as recontamination. The symptom free outcome as well as the rapid reconversion of the polymerase chain reaction test may help to determine the difference between reinfection and recontamination. Awareness of this phenomenon may be valuable in times of human resource difficulties. The available evidence may suggest that the protective value of a prior infection could be better considered for vaccine distribution in the future.

**Key Words:** SARS-CoV-2; COVID-19; Polymerase Chain Reaction; Immunisation; Contamination; Vaccination

Kullmann T, Drozgyik A. Reinfection, recontamination and revaccination for SARS-CoV-2. *World J Methodol* 2022; In press

**Core Tip:** Reinfection: There is not enough evidence of the protective efficacy of the natural immunity induced by a primary infection with severe acute coronavirus 2 (SARS-CoV-2). Recontamination: Testing positive for a second time for SARS-CoV-2 does not necessarily mean a reinfection; it can also be interpreted as recontamination. Revaccination: The available evidence may suggest that the protective value of a prior infection could be better considered for vaccine distribution in the future.

**INTRODUCTION**

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected more than 400 million people worldwide and caused the death of over 6 million[1]. In the last two years SARS-CoV-2 has become the most common cause of death from a single infectious pathogen, preceding *Mycobacterium tuberculosis*, responsible for an estimated 1.4 million victims in 2019[2] and human immunodeficiency virus and malaria, the mortality of which was below 1 million in the last years[3].

The majority of deceased people were retired Caucasians[1]. The geography of the disease expansion may explain why coronavirus, which was most devastating in North America and Europe, received outstanding media and political attention in comparison to other infections with high mortality even if these infections affect young people as much as the elderly. Reports directly showing patients with respiratory assistance in hospital intensive care units were seen by many people for the first time. Beyond the statistical data these widely diffused images contributed to the shocking experience of the pandemic. Coronavirus disease 2019 (COVID-19) is the first pandemic in history to be broadcast live from the beginning on.

There is no efficacious treatment for COVID-19. Hospitalisation may help in those who require oxygen supplementation and in the care of some complications of the disease. Vaccines of different types have been developed to provide protection against infection. This occasion was a world first for the mRNA vaccines[4,5] and the first adenovirus-based vaccine authorized by the US Food and Drug Administration[6]. To date their efficacy in the prevention of severe complications of COVID-19 is evident but their power to reduce disease spread has not met expectations[1].

**REINFECTION**

The first reinfection by a different strain of SARS-CoV-2 was identified in the summer of 2020 with whole genome sequencing and comparative genome analysis in an immunocompetent person with an interval of 142 d between the two episodes[7]. In this case, the primary infection was symptomatic and the reinfection was asymptomatic. A larger analysis of several cases found that the reinfection may be either less severe, or may also have a more severe outcome as compared to the primary infection[8].

When the vaccinations started in spring 2021, follow-up of the protective effect of recovering from a primary infection became problematic, as the promotion of vaccination was so strong in most affected countries, that the majority of the people were vaccinated. Nevertheless, there are some publications available that may help elucidate this issue.

No symptomatic reinfection was detected in 1265 British health care workers who had been followed with positive anti-spike-IgG for 31 wk[9]. In the national, federated database of Qatar there were 350.000 polymerase chain reaction (PCR)-confirmed infections registered between February 28, 2020 and April 28, 2021. Among these cases 1300 reinfections were identified and these cases were matched with primary infections in a 1:5 ratio. The numbers of severe, critical and fatal cases were 158, 28 and 7 for primary infections and 4, 0 and 0 for reinfections, respectively. Vaccinated persons were excluded from the analysis. Severe outcome meant hospitalisation and critical outcome meant hospitalisation in the intensive care unit[10].

These data support the hypothesis that recovering from a primary SARS-CoV-2 infection yields natural immunity that protects from both, potential reinfection and the severe complications of a reinfection. However, vaccinations were declared to provide additional protection.

Breakthrough infections in vaccinated individuals and in those who had a prior infection were compared in the same Qatar database. The PCR cycle threshold is known to inversely correlate with viral load. Or, the cycle threshold value is 1.3 cycles higher for breakthrough infections following the BNT162b2 vaccine, 3.2 cycles higher for breakthrough infections following the mRNA-1273 vaccine, and 4.0 cycles higher for reinfections in unvaccinated individuals than at primary infection. Thus, unvaccinated persons who recovered from a prior SARS-CoV-2 infection had the lowest viral load during a breakthrough infection as compared to their mRNA vaccinated counterparts[11]. In a Bangladesh cohort including 1644 participants, the naturally infected population was less likely to be reinfected by SARS-CoV-2 than the infection-naïve and vaccinated participants with one of the seven different vaccines authorised in this country[12]. A Danish study of 3.800 blood donors who had SARS-CoV-2 PCR positivity found no evidence of a decline in the proportion of detectable anti-SARS-CoV-2 antibodies over time up to 15 mo[13].

In contrast, in a study of 150.000 patients who had recovered from COVID-19 in Israel, those who were vaccinated had a lower risk of reinfection than those who were not vaccinated. The difference was smaller in the elderly population. The study did not report on the severity of the reinfections. The authors recognise that the lack of assessment of disease severity and hospitalisation is an important limitation of their work[14].

**RECONTAMINATION**

The second contact with SARS-CoV-2 is not necessarily a second infection and may only be a contamination, which means that some of the pathogen may be present on the body surface or mucus membrane. However, the invasion of adjacent tissues does not follow, as the person’s defence system prevents it.

Someone contaminated with SARS-CoV-2 will have a positive test, and may possibly and transitionally transmit the virus but will remain asymptomatic. However, the duration of the positivity of a contaminated individual following primary infection or vaccination will be presumably short. In our experience, the duration of their positivity is around 5 d (unpublished data) as compared to the positivity of healthy individuals who undergo a first infection which is at least 8-20 d.

This is in reality what we may expect from the protective efficacy of vaccinations and natural immunity. They do not inhibit the virus reaching the nasal mucosa when in contact with an infected patient. Nevertheless, they provide a more reactive immunity that helps in preventing the development of the disease within the body.

The possible interpretations of a positive SARS-CoV-2 PCR test are summarised in Table 1. Under the pressure of the pandemic it may be difficult to accept that interpretation of the tests depend on the clinical situation; moreover, if the clinical context is omitted, decisions based exclusively on test results may be harmful. The importance of the correct interpretation of sustained PCR positivity at primary infection has been stressed, particularly in the case of comorbidities needing rapid treatment such as certain malignancies[15]. The authorisation of asymptomatic health care workers to return to work has become routine in many hospitals facing problems of human resources. Some other situations when a positive PCR test may be disturbing are listed in Table 2.

**REVACCINATION**

Initially, producers affirmed that two doses one month apart provide immunity for SARS-CoV-2, with the exception of Ad26.COV2-S with which one dose is equivalent to two doses of the other products. However, the level of protective antibodies was found to decrease with time; therefore, the potential necessity for a booster dose was discussed. It is important to note, that the waning of immunity was studied in vaccinated populations whereas for naturally immunised populations there are only observations from case series[16].

Currently, in most Western countries a booster is required 6 mo after the first vaccination for official recognition of protection. The suggestion that the booster may or should be different from the primary vaccine adds to the confusion related to the efficacy of each single vaccine. We agree with the WHO’s consideration that in view of the shortage of vaccines, assuring booster doses for some populations may increase the possibility that other populations will miss even the primary vaccination[16].

In addition, the above-mentioned results[11,12,13] show that natural immunity may even be stronger and last longer than the effect of vaccination depending on both the severity of the infection and the type of vaccination. The distribution of vaccines to non-infected individuals rather than to naturally im-munised individuals would probably have saved more lives and would certainly have been more equitable. This hypothetical redistribution would have concerned hundreds of millions of people.

**DISCUSSION**

One of the destabilising lessons of the pandemic is that scientific predictions concerning COVID-19’s clinical presentation and geographical expansion were rarely correct.

Measures seeming reasonable at one point may be completely useless a couple of weeks later and vice versa. For instance, the nationwide testing in Slovakia in the winter of 2020 drew international attention and the identification of a high number of asymptomatic infections gained recognition. It was assumed that containment of the detected individuals would prevent disease spread. Nevertheless, the country could not avoid the explosion of the disease and the burden on its healthcare system. In contrast, Sweden was much criticised for its liberal management of the pandemic and had a relatively high mortality rate in the first months; however, many more restrictive countries had worse outcomes one year later[1].

Decision making and observance of the prevalence are even more unpredictable than the behaviour of the virus. Decision makers are challenged with opposing expectations but miss essential references. They have to solve dilemmas such as protecting the lives of the elderly *vs* the jobs of the young or the equitable distribution of the vaccines *vs* the most rapid care of their own population. On the other hand observance supposes explanations and never meant obedience.

With the arrival of the Omicron strain there is some hope that after more than two years the disease will pass in a more controllable phase.

**CONCLUSION**

(1) Differentiation between recontamination and reinfection may be useful for persons testing positive for SARS-COV-2 by PCR; (2) The protective effect of prior infection should be considered before vaccination against COVID-19; and (3) Fairness in vaccine distribution should be respected at the global scale.

**REFERENCES**

1 WHO Coronavirus (COVID-19) Dashboard. Last accessed on the 21st April 2022. Available from: covid19.who.int

2 **Chakaya J**, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, Kapata N, Mfinanga S, Hasnain SE, Katoto PDMC, Bulabula ANH, Sam-Agudu NA, Nachega JB, Tiberi S, McHugh TD, Abubakar I, Zumla A. Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts. *Int J Infect Dis* 2021; **113 Suppl 1**: S7-S12 [PMID: 33716195 DOI: 10.1016/j.ijid.2021.02.107]

3 **Bell D**, Schultz Hansen K. Relative Burdens of the COVID-19, Malaria, Tuberculosis, and HIV/AIDS Epidemics in Sub-Saharan Africa. *Am J Trop Med Hyg* 2021; **105**: 1510-1515 [PMID: 34634773 DOI: 10.4269/ajtmh.21-0899]

4 **Polack FP**, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**: 2603-2615 [PMID: 33301246 DOI: 10.1056/NEJMoa2034577]

5 **Baden LR**, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021; **384**: 403-416 [PMID: 33378609 DOI: 10.1056/NEJMoa2035389]

6 **Sadoff J**, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021; **384**: 2187-2201 [PMID: 33882225 DOI: 10.1056/NEJMoa2101544]

7 **To KK**, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, Fong CH, Yuan S, Tsoi HW, Ng AC, Lee LL, Wan P, Tso EY, To WK, Tsang DN, Chan KH, Huang JD, Kok KH, Cheng VC, Yuen KY. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. *Clin Infect Dis* 2021; **73**: e2946-e2951 [PMID: 32840608 DOI: 10.1093/cid/ciaa1275]

8 **Iwasaki A**. What reinfections mean for COVID-19. *Lancet Infect Dis* 2021; **21**: 3-5 [PMID: 33058796 DOI: 10.1016/S1473-3099(20)30783-0]

9 **Lumley SF**, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Warren F, Peck LJ, Ritter TG, de Toledo Z, Warren L, Axten D, Cornall RJ, Jones EY, Stuart DI, Screaton G, Ebner D, Hoosdally S, Chand M, Crook DW, O'Donnell AM, Conlon CP, Pouwels KB, Walker AS, Peto TEA, Hopkins S, Walker TM, Jeffery K, Eyre DW; Oxford University Hospitals Staff Testing Group. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med* 2021; **384**: 533-540 [PMID: 33369366 DOI: 10.1056/NEJMoa2034545]

10 **Abu-Raddad LJ**, Chemaitelly H, Bertollini R; National Study Group for COVID-19 Epidemiology. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. *N Engl J Med* 2021; **385**: 2487-2489 [PMID: 34818474 DOI: 10.1056/NEJMc2108120]

11 **Abu-Raddad LJ**, Chemaitelly H, Ayoub HH, Tang P, Coyle P, Hasan MR, Yassine HM, Benslimane FM, Al-Khatib HA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Khal A, Al-Thani MH, Bertollini R. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. *Nat Commun* 2022; **13**: 532 [PMID: 35087035 DOI: 10.1038/s41467-022-28199-7]

12 **Rahman S**, Rahman MM, Miah M, Begum MN, Sarmin M, Mahfuz M, Hossain ME, Rahman MZ, Chisti MJ, Ahmed T, Arifeen SE, Rahman M. COVID-19 reinfections among naturally infected and vaccinated individuals. *Sci Rep* 2022; **12**: 1438 [PMID: 35082344 DOI: 10.1038/s41598-022-05325-5]

13 **Hønge BL**, Hindhede L, Kaspersen KA, Harritshøj LH, Mikkelsen S, Holm DK, Nilsson AC, Sækmose SG, Sørensen E, Aagaard B, Hjalgrim H, Jørgensen CS, Krause TG, Ullum H, Pedersen OBV, Ostrowski SR, Erikstrup C. Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection. *Int J Infect Dis* 2022; **116**: 289-292 [PMID: 35077881 DOI: 10.1016/j.ijid.2022.01.041]

14 **Hammerman A**, Sergienko R, Friger M, Beckenstein T, Peretz A, Netzer D, Yaron S, Arbel R. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. *N Engl J Med* 2022; **386**: 1221-1229 [PMID: 35172072 DOI: 10.1056/NEJMoa2119497]

15 **Drozgyik A**, Kollár D, Knausz M, Sipőcz I, Molnár FT, Kullmann T. Complex oncologic therapy for loco-regionally advanced breast cancer associated with long-lasting SARS-CoV-2 PCR-positivity. *Orv Hetil* 2021; **162**: 611-614 [PMID: 33830935 DOI: 10.1556/650.2021.32192]

16 WHO. Update December 22, 2021. Last accessed on the 21st April 2022. Available from: https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination

**Footnotes**

**Conflict-of-interest statement:** All the authors declare having no conflict of interest related to the publication of this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 7, 2022

**First decision:** April 12, 2022

**Article in press:**

**Specialty type:** Infectious diseases

**Country/Territory of origin:** Hungary

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Suravajhala PN, India; Vij M, India **S-Editor:** Liu JH **L-Editor:** Webster JR **P-Editor:** Liu JH

**Table 1 Possible meaning of a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2**

|  |  |
| --- | --- |
| **Test result** | **Meaning** |
| True positive result | Asymptomatic infection with SARS-CoV-2 |
| True positive result | Symptomatic infection with SARS-CoV-2 (COVID-19) |
| Sustained positive result | Carriage of virus particles after recovering from COVID-19 |
| False positive result | No infection with SARS-CoV-2 |
| Repeatedly positive result | Reinfection with SARS-CoV-2 |
| Repeatedly positive result | Recontamination with SARS-CoV-2 |

COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

**Table 2 Possible situations, when the misinterpretation of contamination with severe acute respiratory syndrome coronavirus 2 may cause unfair disadvantage for the tested individual**

|  |
| --- |
| **Situations where symptom-free persons can be tested** |
| Being a contact of an infected person |
| Infection control in a health care or social institution |
| Starting a new job |
| Travelling abroad |
| Participating at a controlled event |